The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR and allo-immunity; Saving platelet resources and reducing blood burden.

Inclusion Criteria:

• Patients with ALL，AML，MDS, CML,CLL that suffered from PTR before, with or without HLA antibodies
• The platelet level >150*10E9/L when considering autologous PLT collection
• Age less than 70 years
• The expected life more than 3 months
• Agree to receive autologous platelet cryopreservation and infusion treatment, and sign the informed consent form

Exclusion Criteria:

• Blast cells are found in peripheral blood or bone marrow
• Patients with bacteremia or sepsis
• Coagulation function abnormality
• Patients who have a history of thrombosis and are receiving anticoagulant treatment
• Severe bleeding within 2 weeks
• Participate in another clinical study within 1 month, and have treatment with potential impact on platelets
• Patients with mental disease